{"filings":[{"id":2467997,"accession_number":"0001193125-26-365287","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-08-25T20:57:06+00:00","items":["5.02","9.01"],"status":"ready","headline":"REGENXBIO appoints Greg Ciongoli to board; two directors retire effective Aug 25, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ciongoli elected as independent Class II director, term expires at 2029 annual meeting.","Granted initial equity award with $550,000 fair value (75% option, 25% RSUs), exercise price $8.91, 3-year vesting.","Annual board retainer of $45,000 plus $10,000 audit and $5,000 nominating committee retainers.","Jean Bennett and Jerry Karabelas resigned as directors; will serve as advisors until February 2027.","Board size reduced to nine directors effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2441276,"accession_number":"0001193125-26-363786","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-08-24T21:20:14+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA clinical hold on REGENXBIO's RGX-121 for MPS II; BLA resubmission not expected near term","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clinical hold on RGX-121 after asymptomatic spine MRI findings in 5 CAMPSIITE study participants.","REGENXBIO does not expect to resubmit RGX-121 BLA in near term; longer follow-up and data analysis needed.","All five participants clinically stable/improving; findings deemed nonserious, likely benign by investigators.","Company reaffirms Duchenne BLA submission this quarter and wet AMD pivotal data in Q4.","Hold follows earlier RGX-111 clinical hold; expanded MRI monitoring to include brain and spine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-24","daily_digest_url":"/daily/2026-08-24","daily_digest_rank":5},{"id":2088163,"accession_number":"0001193125-26-336716","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-08-06T11:10:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q2 net income $22.7M; RGX-202 BLA on track; cash runway to Q4 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $22.7M ($0.43 per share) vs net loss of $70.9M in Q2 2025; revenue $108.0M (incl. $100M AbbVie milestone).","RGX-202 Phase III AFFINITY DUCHENNE trial met primary endpoint (p<0.0001); BLA submission on track for Q3 2026 with potential accelerated approval 2H 2027.","RGX-121 BLA resubmission on track for Q3 2026 after positive FDA Type A meeting; no additional studies required.","Sura-vec (ABBV-RGX-314) pivotal wet AMD data expected Q4 2026; first patient dosed in NAAVIGATE DR study triggered $100M milestone.","Pro forma cash ~$313M after July 2026 milestone and public offering; cash runway extended into Q4 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1730316,"accession_number":"0001193125-26-308342","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-07-20T11:34:30+00:00","items":["8.01","9.01"],"status":"ready","headline":"REGENXBIO prices $100M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 10,003,889 shares at $9.00/share and 1,111,111 pre-funded warrants at $8.9999 each.","Gross proceeds ~$100M; net proceeds ~$107.8M after underwriters' full exercise of 1,667,250 option shares.","Underwriters: Morgan Stanley, J.P. Morgan, Leerink Partners, Mizuho Securities.","Expected to close July 20, 2026, subject to customary conditions.","Pre-funded warrants have $0.0001 exercise price, exercisable immediately, no expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1315236,"accession_number":"0001193125-26-286825","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-06-29T11:15:14+00:00","items":["8.01","9.01"],"status":"ready","headline":"REGENXBIO doses first patient in Phase IIb/III DR trial; earns $100M milestone from AbbVie","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase IIb/III NAAVIGATE trial of sura-vec for diabetic retinopathy using suprachoroidal delivery.","Triggered $100M milestone payment from AbbVie, expected in July 2026.","Phase IIb portion to enroll ~135 patients in U.S.; primary endpoint is ≥2-step DRSS improvement at one year.","To present 2.5-year ALTITUDE and 5-year subretinal data at ASRS July 2026.","Topline data from ATMOSPHERE and ASCENT pivotal trials expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":815638,"accession_number":"0001193125-26-254590","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-06-03T11:30:16+00:00","items":["5.07","8.01"],"status":"ready","headline":"REGENXBIO shareholders reject executive stock option exchange; approve non-executive program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At 2026 annual meeting, shareholders voted against executive stock option exchange: 21,021,531 against, 14,097,815 for.","Shareholders approved non-executive stock option exchange: 26,352,456 for, 8,853,230 against. Company commenced program on June 3.","Exchange offer runs June 3–July 1, 2026; eligible options must have exercise price ≥ $18.00.","Directors elected: Jean Bennett, Jerry Karabelas, Daniel Tassé; PwC ratified as auditor; advisory say-on-pay approved.","Program not expected to significantly change stock compensation expense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77564,"accession_number":"0001193125-26-222768","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-05-14T11:15:16+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"REGENXBIO RGX-202 Phase III meets primary endpoint (p<0.0001); Q1 net loss $90.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Primary endpoint achieved: 93% of patients >10% microdystrophin expression at Week 12 (p<0.0001); average expression 71.1%.","Significant correlation between microdystrophin expression and functional improvement (NSAA, p=0.0002); supports surrogate endpoint for accelerated approval.","Q1 2026 net loss $90.1M ($1.72/share) vs prior-year net income $6.1M; revenue fell to $6.4M from $89.0M (prior year milestone).","Cash $150.5M at March 31 (vs $240.9M Dec 31); runway into early 2027; expects $100M AbbVie milestone upon first DR patient dosed in Q2 2026.","FDA lifted clinical hold on RGX-121; company preparing for RGX-202 BLA submission targeting potential accelerated approval in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105924,"accession_number":"0001193125-26-117913","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"REGENXBIO settles GSK sublicense fee dispute for $10M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Company will pay $10.0M to GSK within 3 business days for alleged underpayment of sublicense fees.","Settlement includes mutual releases of past claims and certain future claims under the 2009 license agreement.","Company retains existing allocation methodology for future sublicense fee payments to GSK.","Dispute covered sublicense fees and royalties on amounts received from sublicensees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105923,"accession_number":"0001193125-26-092566","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q4 net loss $67.1M; FDA holds on RGX-121/111; RGX-202 data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $67.1M ($1.30/sh) vs $51.2M loss ($1.01/sh) in Q4 2024; FY net loss $193.9M ($3.76/sh).","Revenues for full year 2025 $170.4M (up from $83.3M in 2024) driven by Nippon Shinyaku partnership and royalty increases.","Cash and marketable securities $240.9M at Dec 31, 2025; expects operations funded into early 2027.","FDA placed clinical holds on RGX-121 and RGX-111; issued Complete Response Letter for RGX-121 BLA in Feb 2026.","RGX-202 for Duchenne: topline pivotal data expected early Q2 2026; pre-BLA meeting mid-2026. Sura-vec wet AMD data expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105922,"accession_number":"0001193125-26-043342","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA rejects REGENXBIO's RGX-121 BLA for MPS II; company plans resubmission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued CRL on Feb 7, 2026 for RGX-121 (clemidsogene lanparvovec) to treat MPS II (Hunter syndrome).","CRL cites uncertainty in defining neuronopathic population, external control comparability, and surrogate endpoint CSF HS D2S6.","FDA suggests new study, additional patients, longer follow-up, or untreated control arm; company calls it 'devastating'.","REGENXBIO plans to request Type A meeting and aim for BLA resubmission with additional data.","Company had believed it addressed FDA's concerns during BLA review; independent experts supported data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105921,"accession_number":"0001193125-26-026139","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA places clinical hold on REGENXBIO's RGX-111 and RGX-121 gene therapies after neoplasm case","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Single neoplasm (intraventricular CNS tumor) found in 5-year-old asymptomatic patient 4 years post-RGX-111 dose; AAV vector integration detected near PLAG1 proto-oncogene.","RGX-121 placed on hold due to product, population, and risk similarities with RGX-111.","No neoplasms reported in 9 other RGX-111 or 32 RGX-121 patients.","CEO surprised by RGX-121 hold while investigation continues; confident in benefit-risk based on positive safety and efficacy data.","Company has not yet received full clinical hold letter and awaits FDA details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122185,"accession_number":"0001193125-25-268101","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO reports Q3 2025 net loss $61.9M; pipeline advances with key milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $61.9M ($1.20/sh) vs $59.6M ($1.17/sh) in Q3 2024; revenue $29.7M (+23% YoY).","Cash, equivalents $302M as of Sep 30, 2025; cash runway into early 2027.","RGX-202 Duchenne pivotal enrollment complete (n=30); topline early Q2 2026, BLA mid-2026.","RGX-121 (MPS II) PDUFA date Feb 8, 2026; CSF biomarker reduction >80% sustained at 1 year.","Sura-vec wet AMD pivotal enrollment complete (n=1,200+); topline Q4 2026."],"consensus_eps_estimate":-1.3316,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":140104000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138910,"accession_number":"0000950170-25-109829","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA extends PDUFA date for RGX-121 BLA to February 8, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PDUFA goal date extended from Nov 9, 2025 to Feb 8, 2026 for review of additional 12-month data from pivotal study (n=13).","No safety concerns raised; pre-license inspection completed with no observations.","Company to present updated pivotal data at ICIEM meeting in September 2025; commercial launch plans remain on track.","RGX-121 would be first potential one-time therapy for MPS II (Hunter syndrome); holds FDA Orphan, Rare Pediatric, Fast Track, RMAT designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138909,"accession_number":"0001193125-25-174947","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"REGENXBIO amends AbbVie deal; restructures $200M milestones, starts DR pivotal; Q2 net loss $70.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to AbbVie collaboration: $100M milestone upon first pt dosed in Phase IIb/III DR trial, additional $100M upon first pt in Phase III.","REGENXBIO to pay costs for Phase IIb of that trial; AbbVie to fund new Phase III wAMD study (ACHIEVE).","Q2 net loss $70.9M ($1.38/share) vs $53.0M loss year ago; revenue $21.4M, down from $22.3M.","Cash $363.6M at June 30, 2025; expects to fund operations into early 2027.","RGX-202 Duchenne pivotal enrollment accelerated, to complete Oct 2025; topline data 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156395,"accession_number":"0000950170-25-080986","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"REGENXBIO stockholders elect four Class I directors, approve 2025 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four Class I directors elected: Fox (27.99M for), Glucksmann (29.26M), Simpson (32.80M), Zachary (29.18M) until 2028.","Ratified PricewaterhouseCoopers as independent auditor for FY2025: 41.17M for, 39,375 against.","Advisory approval of named executive officer compensation: 32.58M for, 1.76M against.","Advisory vote on frequency: 'Every 1 Year' received 33.15M votes; company will hold annual say-on-pay votes.","Approved 2025 Equity Incentive Plan: 27.40M for, 6.97M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156394,"accession_number":"0001193125-25-122456","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"REGENXBIO closes up to $250M royalty bond with HCRx; $150M funded, cash runway into early 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $150M at closing; up to $250M total via three tranches, including $50M contingent on Zolgensma sales threshold by Apr 2027.","Royalty bond bears interest at 9.75% + 3-month SOFR (4.25% floor); repayment solely from royalties on Zolgensma, RGX-121, RGX-111, and NAV platform licensees.","Issued HCRx warrant for 268,096 shares at $14.92 (100% premium to 30-day VWAP), exercisable for 10 years.","Extends expected cash runway into early 2027, funding late-stage programs including RGX-121, RGX-202, and ABBV-RGX-314.","Retains future non-dilutive sources: potential Priority Review Voucher for RGX-121 and milestones from AbbVie and Nippon Shinyaku."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156393,"accession_number":"0000950170-25-069211","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q1 net income $6.1M; revenue up 471% to $89M on Nippon Shinyaku deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $6.1M ($0.12 EPS) vs net loss $63.3M ($1.38 loss) in Q1 2024.","Revenue $89.0M (vs $15.6M) driven by $71.8M license revenue from Nippon Shinyaku partnership.","Cash $272.7M; operations funded into 2H 2026; guidance excludes milestone payments and PRV.","RGX-202 Duchenne pivotal trial >50% enrolled; BLA submission on track for mid-2026.","FDA expected to accept BLA for clemidsogene lanparvovec (RGX-121) in May; potential 2025 approval."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":89012000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174830,"accession_number":"0000950170-25-038711","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO reports Q4 net loss $51.2M; BLA for RGX-121 submitted, Nippon Shinyaku partnership closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $51.2M ($1.01/sh) in Q4 2024 vs $62.9M; full year $227.1M ($4.59/sh) vs $263.5M. Revenue $83.3M vs $90.2M.","BLA for RGX-121 (MPS II) submitted; FDA approval expected 2H 2025. Nippon Shinyaku deal closed: $110M upfront, up to $700M milestones.","RGX-202 Duchenne pivotal trial nearly 50% enrolled; completion expected 2025, BLA mid-2026. Phase I/II data show favorable safety and functional improvement.","Cash and securities $244.9M at Dec 31, 2024 (vs $314.1M). With $110M Nippon upfront, cash runway into 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174829,"accession_number":"0001193125-25-045585","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"REGENXBIO closes strategic partnership with Nippon Shinyaku for MPS gene therapies","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Partnership closed for development/commercialization of RGX-121 (MPS II) and RGX-111 (MPS I) in US and Asia.","RGX-121 on track as first gene therapy for MPS II; potential FDA approval as early as late 2025.","CEO Curran Simpson highlights transformative potential for MPS patient populations.","No financial terms disclosed in this filing; partnership was previously announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174828,"accession_number":"0001193125-25-005659","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"REGENXBIO licenses RGX-121/RGX-111 to Nippon Shinyaku for $110M upfront, up to $700M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront $110M, milestones up to $700M ($40M dev/reg, $660M sales), plus double-digit royalties on net sales in U.S. and Asia.","REGENXBIO retains 100% of proceeds from RGX-121 Priority Review Voucher; rolling BLA submitted, potential FDA approval late 2025.","Nippon Shinyaku to commercialize in Licensed Territory (U.S., Asia); REGENXBIO leads manufacturing and retains rest-of-world rights.","RGX-111 for MPS I (Hurler) also included; Phase 1/2 results promising. Deal expected to close by end of Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191778,"accession_number":"0001193125-24-273467","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"REGENXBIO initiates pivotal phase of RGX-202 Duchenne trial with positive functional data; signs $150M ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First five patients in Phase I/II showed stable/improved function on NSAA and timed tests, exceeding external natural history controls.","FDA alignment achieved on accelerated approval pathway; BLA submission expected in 2026.","Biomarker data: RGX-202 microdystrophin expression highest reported; no serious adverse events.","New ATM sales agreement with Leerink Partners for up to $150M common stock, replacing prior BofA facility.","Pivotal trial enrolling ambulatory patients aged 1+, first patient dosed; includes younger boys aged 1-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191777,"accession_number":"0000950170-24-122300","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q3 net loss $59.6M; cash $278.6M; RGX-202 pivotal trial initiation expected this month","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $59.6M ($1.17 EPS) vs $61.9M ($1.41 EPS) in Q3 2023.","Revenue $24.2M, down from $28.9M, driven by lower Zolgensma royalties ($23.9M vs $28.4M).","Cash, cash equivalents and marketable securities $278.6M as of Sep 30, 2024.","RGX-202 pivotal trial initiation and first functional data expected November 2024.","BLA submission for RGX-121 (MPS II) initiated, expected completion Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":62114000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208257,"accession_number":"0000950170-24-107367","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"REGENXBIO appoints Mitchell Chan as CFO; Vittal Vasista steps down after 15 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mitchell Chan appointed EVP, CFO effective Sept. 16, 2024; base salary $490K, 40% bonus target, $3M equity grant (75% options, 25% RSUs).","Vittal Vasista resigns after 15+ years; separation allowance $500,018 over 3 installments and up to 75% of 2024 targeted bonus.","Vasista will serve as advisor to CEO through Jan. 3, 2025; unvested equity forfeited after advisory period.","Chan brings 20 years biopharma finance experience; prior CFO of Viela Bio (led $3B Horizon acquisition) and operating partner at Catalio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208256,"accession_number":"0001193125-24-194111","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"REGENXBIO grants RSUs to CMO and CSO to promote stability during CEO transition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On August 1, 2024, REGENXBIO granted 58,386 RSUs to EVP/CMO Stephen Pakola and 58,867 RSUs to EVP/CSO Olivier Danos.","RSUs vest over two years with one-fourth vesting every six months, subject to continued service.","Grant aims to retain leadership during a period of CEO transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208255,"accession_number":"0000950170-24-089278","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q2 net loss $53M; advances RGX-202 pivotal and RGX-121 BLA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss of $53.0M ($1.05 per share); revenue $22.3M (up 12% YoY) on Zolgensma royalties.","Cash $327.3M at June 30, 2024; runway into 2026, excluding potential $200M AbbVie milestone.","RGX-202 (Duchenne): consistent high microdystrophin expression; EOP2 supports accelerated approval; pivotal trial start Q4 2024.","RGX-121 (MPS II): rolling BLA submission begins Q3 2024 under accelerated approval pathway.","ABBV-RGX-314 (diabetic retinopathy): EOP2 meeting accelerated to Q4 2024; global pivotal trial planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":37917000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225858,"accession_number":"0001193125-24-160146","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"REGENXBIO appoints COO Curran Simpson as CEO; founder Kenneth Mills becomes Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Curran Simpson, former COO, appointed President and CEO effective July 1, 2024; also named to Board.","Co-founder Kenneth Mills steps down as CEO, becomes Chairman of the Board; advisor until June 2025.","Simpson's compensation: base salary $610k, bonus target 60%, equity grant $2.5M (75% options, 25% RSUs).","Daniel Tassé appointed Lead Independent Director, replacing Jerry Karabelas.","Company reiterates cash guidance: $380.5M as of March 31, 2024, funding ops into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225857,"accession_number":"0000950170-24-068050","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"REGENXBIO annual meeting voting results; all three director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["George Migausky, Kenneth T. Mills, David C. Stump elected as Class III directors with 39.1M, 39.3M, and 35.0M votes for, respectively.","Ratification of PricewaterhouseCoopers as auditor for FY2024: 44.2M for, 58K against, 41K abstain.","Advisory approval of named executive officer compensation: 40.1M for, 727K against, 35K abstain, with 3.3M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225856,"accession_number":"0000950170-24-055656","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q1 net loss $63.3M; RGX-202 selects pivotal dose; cash $380.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.3M ($1.38 diluted EPS) vs $66.7M ($1.53) YoY; revenue $15.6M, down from $19.1M.","Cash, equivalents and marketable securities $380.5M (up from $314.1M), runway into 2026.","RGX-202 Duchenne: pivotal dose DL2 selected; second patient showed 20.9% microdystrophin expression, 90% CK reduction.","ABBV-RGX-314 DR: positive interim ALTITUDE data; end-of-Phase II meeting FDA Q1 2025; pivotal trial H1 2025.","RGX-121 BLA filing on track for 2024 via accelerated approval; potential Priority Review Voucher."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":15622000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244961,"accession_number":"0001193125-24-064353","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"REGENXBIO prices upsized public offering of common stock and pre-funded warrants at $23.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering includes 4,565,260 shares at $23.00 and 1,521,740 pre-funded warrants at $22.9999, with gross proceeds ~$140M.","Net proceeds expected ~$131.2M (or $150.9M if underwriters fully exercise 30-day option for 913,050 additional shares).","Underwriters include Morgan Stanley, Goldman Sachs, Barclays, and Stifel as joint book-running managers.","Pre-funded warrants have $0.0001 exercise price, are exercisable immediately, and do not expire.","Offering expected to close March 11, 2024, under shelf registration statement (File No. 333-269086)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244960,"accession_number":"0000950170-24-021130","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO reports Q4 net loss $62.9M, cash $314M; pipeline milestones for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $62.9M ($1.43/sh); full year net loss $263.5M ($6.02/sh); 2023 revenue $90.2M vs $112.7M in 2022.","Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2023; expected to fund operations into H2 2025.","ABBV-RGX-314 wet AMD subretinal pivotal trials on track for global submissions late 2025-early 2026; suprachoroidal data mid-2024.","RGX-202 Duchenne pivotal dose determination mid-2024; RGX-121 MPS II BLA filing planned for 2024 via accelerated approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":90242000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262416,"accession_number":"0000950170-23-061110","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO cuts 15% workforce, focuses on three lead gene therapies; Q3 net loss $61.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~15%, expected $100M cost savings over two years; cash runway extended into H2 2025.","Q3 revenue $28.9M (Zolgensma royalties $28.4M), net loss $61.9M ($1.41/share) vs $75.5M loss year ago.","Lead programs: ABBV-RGX-314 (wet AMD/DR), RGX-202 (Duchenne), RGX-121 (MPS II); strategic alternatives for others.","ABBV-RGX-314 suprachoroidal data: 89% risk reduction in vision-threatening events at one year for dose level 2.","Cash $364.5M as of Sep 30, 2023, down from $565.2M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279604,"accession_number":"0001193125-23-227647","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"REGENXBIO enters into $150M ATM equity offering agreement with BofA Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May offer and sell common stock up to $150M aggregate price under ATM Sales Agreement with BofA Securities.","Agent will receive commission up to 3% of gross proceeds; sales made at prevailing market prices.","Company not obligated to sell any shares; agreement may terminate at any time by either party.","Offering complements existing S-3 shelf registration filed December 30, 2022.","BofA has provided and may continue providing investment banking and financial services to REGENXBIO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279603,"accession_number":"0000950170-23-037162","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q2 net loss $72.1M ($1.66/sh); revenue $20M; RGX-121 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $72.1M vs $68.2M YoY; diluted EPS -$1.66.","Revenue fell to $20.0M from $32.6M; Zolgensma royalty revenue down to $19.0M.","Cash, equivalents and marketable securities $415.4M; runway into 2025.","Completed enrollment (10 patients) in Phase III CAMPSIITE trial for RGX-121; BLA filing planned 2024.","ABBV-RGX-314 suprachoroidal dose level 3 with short-course steroids showed zero intraocular inflammation (N=39)."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":39115000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298009,"accession_number":"0000950170-23-026437","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"REGENXBIO shareholders elect all three Class II director nominees at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jean Bennett, Jerry Karabelas, and Daniel Tassé elected as Class II directors with 30.3M, 35.5M, and 36.0M votes for, respectively.","Ratification of PricewaterhouseCoopers as independent auditor for FY2023 approved: 39.8M for, 50.7K against.","Advisory (non-binding) vote on named executive officer compensation passed with 36.7M for, 1.1M against.","Broker non-votes were 1,965,878 for director election and say-on-pay; none for auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298008,"accession_number":"0000950170-23-017184","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q1 net loss $66.7M ($1.53/share); cash $473.5M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $473.5M as of Mar 31, 2023; runway into 2025.","Revenue $19.1M, down from $22.2M YoY mainly due to lower Zolgensma royalties ($16.1M vs $21.5M).","Net loss $66.7M ($1.53 per share) vs $76.7M ($1.79) YoY; R&D spend up to $58.5M.","Subretinal ABBV-RGX-314 pivotal trials expanded; regulatory submissions expected late 2025 to H1 2026.","RGX-202 Duchenne trial on track for initial data H2 2023; RGX-121 BLA filing planned in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":19138000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318258,"accession_number":"0000950170-23-005077","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q4 net loss $59.9M ($1.38/share); revenue $31.3M vs $398.7M YoY; cash $565M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 net loss $280.3M ($6.50/share) vs net income $127.8M in 2021.","Revenue fell to $112.7M in 2022 from $470.3M, driven by $370M non-recurring AbbVie collaboration revenue in 2021.","Zolgensma royalties rose to $101.9M in 2022 from $95.0M in 2021.","Cash, equivalents and marketable securities $565.2M as of Dec 31, 2022, down from $849.3M; runway into 2025.","RGX-314 pivotal trials ongoing with BLA expected in 2024; RGX-121 pivotal enrollment to complete H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":112724000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318257,"accession_number":"0001193125-23-005019","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"REGENXBIO promotes Curran Simpson to COO, Shiva Fritsch to Chief Communications Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Curran Simpson appointed COO effective Jan 9, 2023; previously SVP, Chief Technology and Operations Officer since 2015.","Shiva Fritsch elevated to Chief Communications Officer while retaining Chief People Officer role; joined REGENXBIO in 2017.","Promotions follow opening of Manufacturing Innovation Center and progress toward '5 x '25' strategy for five AAV therapeutics.","Simpson will oversee manufacturing, quality, regulatory, preclinical development, and corporate strategy.","Fritsch will oversee internal/external communications and human resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336537,"accession_number":"0000950170-22-021548","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q3 net loss $75.5M; cash $617M; RGX-314 BLA on track for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $75.5M ($1.75/share) vs $58.4M ($1.37/share) in Q3 2021; revenue $26.5M, down from $30.8M.","Cash, equivalents & marketable securities $617M as of Sept 30, 2022, down from $849.3M at Dec 31, 2021; runway into 2025.","RGX-314 subretinal pivotal trials (ATMOSPHERE, ASCENT) enrolling; BLA filing planned in 2024. AAVIATE and ALTITUDE trials expanded with new cohorts.","RGX-202 AFFINITY DUCHENNE Phase I/II trial on track for first patient dosing in H1 2023; RGX-121 CAMPSIITE pivotal trial enrolling for MPS II.","Zolgensma royalty revenue $25.2M in Q3 2022 vs $30.3M in Q3 2021; Novartis reported Q3 global sales of $319M."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":81379000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353940,"accession_number":"0001564590-22-027754","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q2 net loss $68.2M, revenues up 48%; RGX-314 BLA on track for 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $68.2M ($1.58/share) vs $57.6M ($1.36) in Q2 2021; revenues $32.6M up 48% YoY.","Cash and marketable securities $682M (down from $849M Dec 2021); runway into 2025.","RGX-314 (wet AMD/DR) on track for BLA in 2024; pivotal trials enrolling; AAVIATE Cohort 5 complete; ALTITUDE enrollment complete.","RGX-121: intend to file BLA in 2024 via accelerated approval; pivotal CAMPSIITE trial active enrolling up to 10 patients.","RGX-202 first patient dosing expected in first half 2023; NAV licensee Zolgensma Q2 sales $379M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":54867000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371782,"accession_number":"0001193125-22-168821","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"REGENXBIO appoints Jennifer Zachary to board; annual meeting results ratified","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Zachary elected Class I director and Audit Committee member, effective June 3, 2022.","Ms. Zachary receives initial equity award of $550,000 (75% option, 25% RSUs) at $22.84 exercise price.","Annual meeting re-elected Allan Fox and Alexandra Glucksmann as Class I directors; PwC ratified as auditor.","Advisory vote on named executive officer compensation approved with 96% of votes cast in favor.","Ms. Zachary is EVP & General Counsel of Merck, bringing 20+ years of pharma and regulatory experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371781,"accession_number":"0001564590-22-017853","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q1 net loss widens to $76.7M; delays RGX-202 Duchenne trial initiation to H1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $76.7M ($1.79/sh) vs $50.1M loss ($1.20/sh) in Q1 2021; revenue $22.2M up 17% YoY on Zolgensma royalties.","Cash $764.8M, operational runway into 2025; net loss includes $9.2M non-recurring charge from UPenn license amendment.","RGX-314 pivotal trials for wet AMD on track; BLA submission expected in 2024.","RGX-202 Duchenne trial dosing delayed to H1 2023 due to manufacturing observation; trial prep continues.","cGMP manufacturing facility operational for up to 2000L scale; '5x'25' strategy to advance five AAV therapeutics by 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":22218000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390722,"accession_number":"0001193125-22-085244","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2022-03-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"REGENXBIO settles Penn sublicense fees with $8M payment and $12M over 4 years; future fees removed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company pays $8.0M to Penn for sublicense fees related to AbbVie collaboration agreement.","Company will pay $12.0M over four years ($3M annually) to satisfy past/future sublicense obligations.","Letter agreement deletes Section 3.5 of Penn-REGENXBIO License, removing obligation to pay future sublicense fees.","Penn gains right to conduct gene therapy research outside a single identified field, with no restriction.","Parties agree to explore further expansion of relationship, including new collaboration and alliance opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390721,"accession_number":"0001193125-22-079590","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2022-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"REGENXBIO director Daniel Abdun-Nabi will not stand for re-election at 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel J. Abdun-Nabi informed REGENXBIO he will not stand for re-election at the 2022 annual meeting.","His term expires at the 2022 annual meeting; decision not due to any disagreement with the company.","He served nearly six years as a director; company thanked him for his service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390720,"accession_number":"0001564590-22-008037","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO reports Q4 net income $294M on AbbVie deal; cash $849M into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net income $294M ($6.87 basic EPS) vs net loss $46.2M in Q4 2020; revenue $398.7M (incl $370M AbbVie upfront).","Cash, equivalents & marketable securities $849.3M at Dec 31, 2021; runway into 2025.","Closed eye care collaboration with AbbVie: $370M upfront + up to $1.38B milestones; two pivotal trials (ATMOSPHERE, ASCENT) for wet AMD.","RGX-202: FDA cleared IND, granted Rare Pediatric Disease & Orphan Drug designations; Phase I/II AFFINITY DUCHENNE trial to start H1 2022.","RGX-314 suprachoroidal: Phase II AAVIATE (wet AMD) & ALTITUDE (DR) show reduced treatment burden; enrollment in higher-dose cohorts ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":2.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":470347000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390719,"accession_number":"0001193125-22-039357","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"REGENXBIO RGX-314 Phase II ALTITUDE: 47% patients achieve ≥2-step DRSS improvement at 6 months vs 0% control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["47% of RGX-314 patients in Cohort 1 showed ≥2-step DRSS improvement at 6 months vs 0% control; up from 33% at 3 months.","No drug-related serious adverse events or intraocular inflammation in 15 patients at 6 months; therapy well tolerated.","Among NPDR patients (severity 47-53), 57% achieved ≥2-step improvement; among PDR patients, 38% achieved improvement.","Enrollment ongoing for Cohorts 2 (5x10^11 GC/eye) and 3 (NAb-positive patients) with no prophylactic corticosteroid use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390718,"accession_number":"0001193125-22-032205","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"REGENXBIO reports positive interim Phase I/II data for RGX-121 (MPS II) and RGX-111 (MPS I)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Both RGX-121 (13 pts) and RGX-111 (5 pts + single-patient IND) well-tolerated with no drug-related SAEs.","RGX-121: Dose-dependent CSF biomarker reductions; Cohort 3 D2S6 near normal levels at last follow-up.","RGX-111: CSF heparan sulfate decreased in all 4 patients; IDUA enzyme detected in 3 of 4 post-dose.","Neurodevelopmental improvement: RGX-121 patients (Cohorts 1-2) show skill acquisition up to 2 years; RGX-111 shows gains in younger and one older patient.","Next steps: RGX-121 Cohort 3 expansion with cGMP material planned 1H2022; RGX-111 Cohort 2 expanded to enroll up to 6 more patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408803,"accession_number":"0001193125-21-328962","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"REGENXBIO settles arbitration with Abeona, receives $30M total payment","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Abeona pays $20M upfront (received); $5M due at first anniversary; $5M due by third anniversary or specified transaction.","Settlement resolves arbitrations and related proceedings from terminated November 2018 License Agreement.","Parties will dismiss enforcement action and second arbitration; mutual release of claims.","Company expects to file full Settlement Agreement with 2021 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408802,"accession_number":"0001193125-21-328180","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"REGENXBIO reports positive interim Phase II data for RGX-314; 71.8% reduction in anti-VEGF injections at 6 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RGX-314 well tolerated across 50 patients in Cohorts 1-3; no drug-related SAEs.","Cohort 2 (wet AMD) at 6 months: mean BCVA stable (-0.1 letters from Day1); 71.8% reduction in anti-VEGF burden; 40% injection-free.","Cohort 1 (diabetic retinopathy) at 3 months: stable BCVA +2.6 letters vs +0.4 control.","Company plans additional updates; enrollment ongoing in higher-dose cohorts 4/5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408801,"accession_number":"0001193125-21-324463","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"REGENXBIO closes $370M upfront eye care collaboration with AbbVie for RGX-314 gene therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $370M; potential for up to $1.38B in development, regulatory, and commercial milestones.","REGENXBIO and AbbVie to share equally in US profits; AbbVie to pay tiered royalties on ex-US net sales.","REGENXBIO responsible for ongoing trials; AbbVie leads global clinical development and commercialization.","REGENXBIO to lead manufacturing for clinical and US commercial supply; AbbVie for ex-US commercial supply.","Agreement covers RGX-314 for wet AMD, diabetic retinopathy, and other chronic retinal diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408800,"accession_number":"0001564590-21-053557","cik":1590877,"company_name":"REGENXBIO Inc.","ticker":"RGNX","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"REGENXBIO Q3 net loss $58.4M; AbbVie collaboration for RGX-314 with $370M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["AbbVie collaboration: $370M upfront, up to $1.38B milestones, 50/50 U.S. profit share.","Q3 revenue $30.8M (prior year $98.9M included $80M milestone); net loss $58.4M vs prior year net income $8.8M.","Cash $533.5M; expects to fund operations into H2 2023, excluding AbbVie deal proceeds.","RGX-314 Phase II: stable visual acuity and reduced anti-VEGF burden in wet AMD; 33% of DR patients improved ≥2 steps.","IND for RGX-202 for Duchenne muscular dystrophy on track for end of 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":71692000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":354128702.32436466,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-02T23:59:59+00:00|408800"}